Search


Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS
CEO Neil Miller walks us through the hypothesis of how toxic proteins created by neurodegenerative diseases enter and damage the...
Sep 8








.png)




